Patents Assigned to University of Oxford
-
Patent number: 8703744Abstract: Provided are methods of reducing cellular cholesterol levels using lipid particles that are capable of cellular entry. Such lipid particles may be used for treating or preventing a disease or condition that is caused by or associated with an increased cellular cholesterol level and for treating or preventing a disease or condition, that is caused by or associated with a virus, that relies on cellular cholesterol for its replication.Type: GrantFiled: March 26, 2010Date of Patent: April 22, 2014Assignee: The Chancellor, Masters and Scholars of the University of OxfordInventors: Stephanie Pollock, Raymond Dwek, Nicole Zitzmann
-
Publication number: 20140085446Abstract: The present invention provides an optical device for a visually-impaired individual and a method of operating such a device. In one embodiment, the apparatus comprises a spaced array of discrete light sources and a support arranged to maintain the array in proximate relation to at least one eye of the visually-impaired individual. An image capture device is configured to capture images of at least part of the individual's immediate environment, wherein the array is configured to convey information to the individual by selectively illuminating one or more of the discrete light sources based on the content of the captured images. In this way, information relating to objects and/or textual language in the individual's environment can be conveyed to the individual by predetermined patterns of illumination (e.g. spatial and/or temporal). The apparatus and method are found to be particularly suited for visually-impaired individuals who retain at least some residual light and/or colour discrimination.Type: ApplicationFiled: February 24, 2012Publication date: March 27, 2014Applicant: Clinic Neurosciences, University of OxfordInventor: Stephen Hicks
-
Publication number: 20140080769Abstract: The present invention provides a compound which is an inhibitor of sphingolipid biosynthesis for use in the treatment of a disease which has a secondary Niemann-Pick type C disease like cellular phenotype.Type: ApplicationFiled: September 13, 2013Publication date: March 20, 2014Applicants: The Chancellor, Masters and Scholars of the University of Oxford, The Government of the United States of America, as represented by the Secretary, Department of HealtInventors: Frances Mary Platt, Emyr Lloyd-Evans, Forbes Dennison Porter
-
Patent number: 8663459Abstract: Sulfur-containing compounds, including specifically thiophenic compounds, in a liquid hydrocarbon feedstream are catalytically oxidized by combining the hydrocarbon feedstream with a catalytic reaction mixture that includes a peroxide that is soluble in water or in a polar organic acid, at least one carboxylic acid, and a catalyst that is a transition metal salt selected from the group consisting of (NH4)2WO4, (NH4)6W12O40.H2O, Na2WO4, Li2WO4, K2WO4, MgWO4, (NH4)2MoO4, (NH4)6Mo7O24.4H2O, MnO0 and NaVO3; the mixture is vigorously agitated for a time that is sufficient to oxidize the sulfur-containing compounds to form sulfoxides and sulfones; the reaction mixture is allowed to stand and separate into a lower aqueous layer containing the catalyst and an upper hydrocarbon layer that is recovered and from which the oxidized sulfur compounds are removed, as by solvent extraction, distillation or selective adsorption.Type: GrantFiled: March 5, 2007Date of Patent: March 4, 2014Assignees: Saudi Arabian Oil Company, The Chancellor, Masters and Scholars of the University of OxfordInventors: Farhan M. Al-Shahrani, Tiancun Xiao, Gary Dean Martinie, Malcolm L. H. Green
-
Patent number: 8557844Abstract: The present invention provides a compound which is an inhibitor of sphingolipid biosynthesis for use in the treatment of a disease which has a secondary Niemann-Pick type C disease like cellular phenotype.Type: GrantFiled: June 26, 2008Date of Patent: October 15, 2013Assignees: The Chancellor, Masters and Scholars of the University of Oxford, The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Frances Mary Platt, Emyr Lloyd-Evans, Forbes Dennison Porter
-
Publication number: 20130237567Abstract: Provided are methods of treating or preventing viral infections caused by or associated with a Dengue virus using iminosugars.Type: ApplicationFiled: April 25, 2013Publication date: September 12, 2013Applicants: The Chancellor, Masters and Scholars of the University of Oxford, United Therapeutics CorporationInventors: Urban Ramstedt, Brennan Klose, Nicole Zitzmann, Raymond A. Dwek, Terry D. Butters
-
Patent number: 8501999Abstract: The process provided herein is concerned with recovery of hydrocarbons from sulfones using an individual alkali and alkaline-earthy base and a mixture of thereof. As the starting materials are sulfones generated by ODS and commercially inexpensive alkali and alkaline-earth bases, the cost and ecological impact of solid waste disposal is minimized.Type: GrantFiled: November 4, 2010Date of Patent: August 6, 2013Assignees: Saudi Arabian Oil Company, The Chancellor, Masters and Scholars of the University of OxfordInventors: Farhan M. Al-Shahrani, Tiancun Xiao, Huahong Shi, Malcolm L. H. Green
-
Publication number: 20130195798Abstract: One can treat a viral infection by first administering at least one first antiviral compound for a first time period and then, after the end of the first time period, concurrently or subsequently administering the at least one first antiviral compound and at least one second antiviral compound for a second period. In some cases, after the end of the second period, the same at least one second antiviral compound that was administered during the second time period may be administered for a third time period without concurrent or subsequent administration of the at least one first antiviral compound.Type: ApplicationFiled: November 21, 2012Publication date: August 1, 2013Applicants: The Chancellors, Masters and Scholars of the University of Oxford, United Therapeutics CorporationInventors: United Therapeutics Corporation, The Chancellors, Masters and Scholars of the Univ
-
Publication number: 20130150405Abstract: Provided are novel methods of treating and/or preventing a disease or condition caused by or associated with a virus belonging to the Togaviridae family using iminosugars, such as DNJ derivatives.Type: ApplicationFiled: February 7, 2013Publication date: June 13, 2013Applicants: The Chancellor, Masters and Scholars of the University of Oxford, United Therapeutics CorporationInventors: United Therapeutics Corporation, The Chancellor, Masters and Scholars of the University of Oxford
-
Patent number: 8450345Abstract: Provided are methods of treating or preventing viral infections caused by or associated with a Dengue virus using iminosugars.Type: GrantFiled: February 22, 2010Date of Patent: May 28, 2013Assignees: The Chancellor, Masters and Scholars of the University of Oxford, United Therapeutics CorporationInventors: Urban Ramstedt, Brennan Klose, Nicole Zitzmann, Raymond A. Dwek, Terry D. Butters
-
Patent number: 8426445Abstract: Provided are novel methods of treating and/or preventing a disease or condition caused by or associated with a virus belonging to the Bunyaviridae or Togaviridae family using iminosugars, such as DNJ derivatives.Type: GrantFiled: June 11, 2010Date of Patent: April 23, 2013Assignees: United Therapeutics Corporation, The Chancellor, Masters and Scholars of the University of OxfordInventors: Urban Ramstedt, Brennan Klose, Nicole Zitzmann, Raymond A. Dwek, Terry D. Butters
-
Patent number: 8367705Abstract: Provided are novel methods of treating and/or preventing a disease or condition caused by or associated with a virus belonging to the Bunyaviridae or Togaviridae family using iminosugars, such as DNJ derivatives.Type: GrantFiled: June 11, 2010Date of Patent: February 5, 2013Assignees: United Therapeutics Corporation, The Chancellor, Masters and Scholars of the University of OxfordInventors: Urban Ramstedt, Brennan Klose, Nicole Zitzmann, Raymond A. Dwek, Terry D. Butters
-
Patent number: 8188313Abstract: Compounds of formula wherein the variable are defined in the specification, are used in compositions which stimulate T cell responses.Type: GrantFiled: September 13, 2011Date of Patent: May 29, 2012Assignees: The University of Birmingham, Chancellor Masters and Scholars of the University of Oxford, Ludwig Institute for Cancer ResearchInventors: Vincenzo Cerundolo, Richard Schmidt, Gopal Reddy, Rengarajan Balamurugan, Gerd Ritter, Gurdyal Besra, Mariolina Salio, Jonathan Silk
-
Patent number: 8039670Abstract: There are disclosed compound of formula I, in which R1 represents a hydrophobic moiety adapted to occupy the C? channel of human CDId, R2 represents a hydrophobic moiety adapted to occupy the A? channel of human CDId, such that R1 fills at least at least 30% of the occupied volume of the C? channel compared to the volume occupied by the terminal nC14H29 of the sphingosine chain of ?-galactosylceramide when bound to human CDId and R2 fills at least 30% of the occupied volume of the A? channel compared to the volume occupied by the terminal nC25H51 of the acyl chain of ?-galactosylceramide when bound to human CDId R3 represents hydrogen or OH, Ra and Rb each represent hydrogen and in addition, when R3 represents hydrogen, Ra and Rb together may form a single bond, X represents or —CHA(CHOH)nY or —P(=0)(0?)0CH2(CH0H)mY, in which Y represents CHB1B2, n represents an integer from 1 to 4, m represents 0 or 1, A årepresents hydrogen, one of B1 and B2 represents H, OH or phenyl, and the other represents hydrogen or oType: GrantFiled: October 25, 2006Date of Patent: October 18, 2011Assignees: Ludwig Institute for Cancer Research, Chancellor Master and Scholars of the University of Oxford, The University of BirminghamInventors: Vincenzo Cerundolo, Richard Schmidt, Gopal Reddy, Rengarajan Balamurugan, Gerd Ritter, Gurdyal Besra, Mariolina Salio, Jonathan Silk
-
Patent number: 7816560Abstract: Long chain N-alkyl amino and imino compounds, oxa-substituted derivatives thereof, and pharmaceutical compositions including such compounds are described. The long chain N-alkyl group is a C8-C16 alkyl group. The long chain N-alkyl compounds and oxa-substituted derivatives thereof can be used in the treatment of viral infections, in particular hepatitis B virus or hepatitis C virus, in a cell or an individual. For example, the long chain N-alkyl compounds or oxa-substituted derivatives thereof can be derived from piperidines, pyrrolidines, phenylamines, pyridines, pyrroles, or amino acids.Type: GrantFiled: August 10, 2000Date of Patent: October 19, 2010Assignees: Thomas Jefferson University, The Chancellor, Masters and Scholars of the University of Oxford, United Therapeutics CorporationInventors: Nicole Zitzmann, Terry D. Butters, Frances M. Platt, Gary S. Jacob, Donald H. Picker, Sandra Carrouee, George W. J. Fleet, Raymond A. Dwek, David Durantel, Anand Mehta, Timothy M. Block
-
Patent number: 7803382Abstract: The invention provides methods, compositions and kits for inducing and/or enhancing an immune response in a subject. The invention in some aspects includes polypeptide and nucleic acid molecules that induce and/or enhance an immune response. In some aspects of the invention, the polypeptide and/or nucleic acid molecules of the invention are useful to induce and/or enhance an immune response in a subject who has or is suspected of having cancer.Type: GrantFiled: September 9, 2004Date of Patent: September 28, 2010Assignees: Ludwig Institute for Cancer Research Ltd., Chancelors Masters and Scholars of the University of OxfordInventors: Lloyd J. Old, Sacha Gnjatic, Djordje Atanackovic, Vincenzo Cerundolo, Khoon-Lin Ling
-
Publication number: 20100092384Abstract: Provided is a multifunctional particle comprising: (a) an inner metallic core, (b) a biocompatible shell comprising an optical contrast agent embedded therein, and (c) a targeting biomolecule conjugated to the biocompatible shell through a multidentate ligand, wherein the multidentate ligand is chelated to an imaging agent. Also provided are compositions comprising the multifunctional particle and methods of using the multifunctional particle, including a method of diagnostic imaging and a method of treatment.Type: ApplicationFiled: March 17, 2008Publication date: April 15, 2010Applicants: The jUnited States of America as represented by Secretary, Dept. of Health and Human Service, University of OxfordInventors: Ambika Bumb, Martin W. Brechbiel, Peter Choyke, Lars Fugger, Peter James Dobson
-
Publication number: 20090041776Abstract: The invention as described herein provides compositions and methods for cancer immunotherapy and cancer detection. In particular, the invention discloses plant-derived human monoclonal antibodies that bind human carcinoma antigens in cancer cell lines.Type: ApplicationFiled: April 23, 2008Publication date: February 12, 2009Applicants: Biotechnology Foundation, Inc., The Chancellor, Masters and Scholars of the University of Oxford, University of OxfordInventors: Hilary Koprowski, Kisung Ko, Pauline Rudd, Yoram Tekoah, Raymond Dwek
-
Publication number: 20080226664Abstract: The invention provides methods, compositions and kits for inducing and/or enhancing an immune response in a subject. The invention in some aspects includes polypeptide and nucleic acid molecules that induce and/or enhance an immune response. In some aspects of the invention, the polypeptide and/or nucleic acid molecules of the invention are useful to induce and/or enhance an immune response in a subject who has or is suspected of having cancer.Type: ApplicationFiled: September 9, 2004Publication date: September 18, 2008Applicants: Ludwig Institute for Cancer Research, Chancellors Masters and Scholars of the University of OxfordInventors: Lloyd J. Old, Sacha Gnjatic, Djordje Atanackovic, Vincenzo Cerundolo, Khoon-Lin Ling
-
Patent number: 7364739Abstract: The present invention relates to a lipopolysaccharide moiety comprising a conserved triheptosyl inner-core moiety of lipopolysaccharide substantially free of variable outer core oligosaccharide chain extension, and to vaccines obtaines therefrom which are cross-reactive for Haemophilus influenzae strains. The invention also relates to defined mutations in the biosynthetic machinery for lipopolysaccharide (LPS;) expression in Haemophilus influenzae useful to obtain the abovementioned moiety. The invention also relates to using conjugates of the LPS from the mutant strains so obtained to elicit a heterologous immune response against a wide range of disease-causing H. influenzae strains. More specifically, the invention relates to vaccines for prevention of bacterial infections comprising core lipopolysaccharide of Haemophilus influenzae.Type: GrantFiled: August 27, 2001Date of Patent: April 29, 2008Assignees: National Research Council of Canada, The Chancellor, Masters, and Scholars of the University of OxfordInventors: James C. Richards, Andrew Cox, Richard Moxon, Derek Hood, Elke K. H. Schweda, Martin Månsson